Recent advances in primary cutaneous T-cell lymphoma. [Review] []

MedStar author(s):
Citation: Current Opinion in Oncology. 27(2):128-33, 2015 Mar.PMID: 25594623Institution: MedStar Washington Hospital CenterDepartment: DermatologyForm of publication: Journal ArticleMedline article type(s): Journal Article | Research Support, Non-U.S. Gov't | ReviewSubject headings: *Antineoplastic Agents, Alkylating/ad [Administration & Dosage] | *Immunologic Factors/ad [Administration & Dosage] | *Lymphoma, T-Cell, Cutaneous/dt [Drug Therapy] | *Phototherapy/mt [Methods] | *Skin Neoplasms/dt [Drug Therapy] | *Stem Cell Transplantation/mt [Methods] | Combined Modality Therapy | Humans | Lymphoma, T-Cell, Cutaneous/pa [Pathology] | Phototherapy/td [Trends] | Skin Neoplasms/pa [Pathology] | Stem Cell Transplantation/td [Trends]Local holdings: Available online from MWHC library: 1999 - presentISSN:
  • 1040-8746
Name of journal: Current opinion in oncologyAbstract: PURPOSE OF REVIEW: Cutaneous T-cell lymphoma (CTCL) is a heterogeneous group of skin-homing T-cell neoplasms, which represent approximately 75% of all primary cutaneous lymphomas. Currently available drug therapies, when effective, simply control disease and the only option for curing CTCL is stem cell transplant.RECENT FINDINGS: In the last year, there has been an incredible effort made to improve the understanding and treatment of CTCL. Recent findings indicate that epigenetic aberrations are integral to active disease. Furthermore, multiple tumor-derived immunological factors have also been shown to inhibit viability, proliferation, and cytokine production of nonmalignant T cells. Several novel targeted therapies show great potential, most promising being antibody drug conjugates targeting surface markers such as CD30 in some CTCL subtypes. Additional attractive targets involve the global modulation of epigenetic markers such as demethylation agents or HDAC inhibitors, either as single agents or in combination therapies.SUMMARY: This is a concise review of recent advances in the field of CTCL with special focus on research articles over the preceding year.All authors: Cozzio A, DeSimone JA, Dummer R, Guenova E, Ignatova D, Sodha PDigital Object Identifier: Date added to catalog: 2016-01-13
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article Available 25594623

Available online from MWHC library: 1999 - present

PURPOSE OF REVIEW: Cutaneous T-cell lymphoma (CTCL) is a heterogeneous group of skin-homing T-cell neoplasms, which represent approximately 75% of all primary cutaneous lymphomas. Currently available drug therapies, when effective, simply control disease and the only option for curing CTCL is stem cell transplant.

RECENT FINDINGS: In the last year, there has been an incredible effort made to improve the understanding and treatment of CTCL. Recent findings indicate that epigenetic aberrations are integral to active disease. Furthermore, multiple tumor-derived immunological factors have also been shown to inhibit viability, proliferation, and cytokine production of nonmalignant T cells. Several novel targeted therapies show great potential, most promising being antibody drug conjugates targeting surface markers such as CD30 in some CTCL subtypes. Additional attractive targets involve the global modulation of epigenetic markers such as demethylation agents or HDAC inhibitors, either as single agents or in combination therapies.

SUMMARY: This is a concise review of recent advances in the field of CTCL with special focus on research articles over the preceding year.

Powered by Koha